Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Inupadenant - iTeos Therapeutics

Next Previous
X
Search
Drug Profile

Inupadenant - iTeos Therapeutics

Alternative Names: EOS-100850; EOS-850; Inupadenant hydrochloride

Latest Information Update: 17 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator iTeos Therapeutics
  • Class 3-ring heterocyclic compounds; Amines; Antineoplastics; Fluorobenzenes; Furans; Organic sulfur compounds; Piperazines; Pyrimidines; Small molecules; Thiazoles
  • Mechanism of Action Adenosine A2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Malignant melanoma; Non-small cell lung cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 17 May 2024 iTeos Therapeutics completes enrolment in its phase II trial for NSCLC (Combination therapy, Metastatic disease, Second-line therapy or greater) in Belgium, Poland, USA, Spain, Czech republic, France, Italy, Switzerland, Canada (country/ies) (NCT05060432)
  • 01 Jan 2024 iteo therapeutics has patent protection for inupadenant in the US, Autralia, Europe and China
  • 10 May 2023 Pharmacodynamics data from a preclinical trial in Cancer released by iTeos Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top